Distribution of drug-resistant HIV-1 variants after complex antiretroviral prophylaxis in 50 Tanzanian women.

<p>Distribution of drug-resistant HIV-1 variants after complex antiretroviral prophylaxis in 50 Tanzanian women.</p

Oligonucleotide sequences of primers used in outer and allele-specific PCR (ASPCR).

<p>Oligonucleotide sequences of primers used in outer and allele-specific PCR (ASPCR).</p

Drug-resistant HIV-1 variants in plasma samples of seven children HIV-1 infected by vertical transmission as analyzed by allele-specific PCR (ASPCR).

<p>wt = wild-type HIV-1.</p><p>n/a = not amplifiable.</p><p>- = no sample.</p><p># = sample collected at day 3.</p><p>* = also detected by population-based sequencing.</p><p>° = not detected by population-based sequencing.</p

BED-CEIA, Bio-Rad Avidity and Lag-Avidity results according to duration of infection.

<p>Samples from the evaluation panel were analyzed using the BED capture enzyme immunoassay (A), Bio-Rad Avidity assay (B) and LAg-Avidity enzyme immunoassay (C). Respective assay cut-offs are indicated by the black line. Data are shown for subsets of the evaluation panel.</p

Characteristics of evaluation panel.

<p>IQR = Interquartile range, SC = seroconverter, d = days, wk = weeks.</p

Comparison of BED-CEIA, Bio-Rad and LAg-Avidity assay results according to subtype, clinical stage and disease progression.

<p>True recent ratios within the ‘recent infections set’ subtype B and ‘non-B’ (A). False recent ratios among long-term subtype B and ‘non-B’ infected, ARV-naïve individuals (B). Misclassification in the ‘challenge specimens’ set (C). Only significant p-values (<0.05) of pairwise comparisons were indicated.</p

Comparison of UDS, ASPCR, and Sanger sequencing.

<p>c/ml copies per ml; n.a. not analysed; wt wild type sequence (Sanger); wt no key resistance mutation detected</p><p>Comparison of UDS, ASPCR, and Sanger sequencing.</p